Lupin Ltd management interview: Lupin Q2 Outlook: Brazil Competition, US Pipeline & India Growth Plans Explained | Business News
ET Now, 2026-11-05. Video: https://www.youtube.com/watch?v=oxPDQilwRHw
- Tolvaptan and margins: Lupin retained a decent share after building 50% share for generics over 1 year, but further competition is expected to pressure pricing. Management ruled out raising FY27 EBITDA margin guidance of 24 to 25%; Swaminathan said it aims to sustain 23-24 for the full year and expects possible slight erosion in FY28.
- India growth: Lupin is the third-largest generic Semaglutide player in India and aims to become the largest, with vial and oral launches targeted by the end of the financial year. Respiratory growth is expected to strengthen in the second half across inhalation MDIs and DPIs and nebulization.
- US pipeline: Management expects US growth to return from FY28, driven by 505(b)(2), biosimilars and complex respiratory generics. Apixaban should be meaningful in FY28; pegfilgrastim and ranibizumab are expected in the next year, with Dulera and Respimat products contributing in FY29.
- Adjacent businesses: Diagnostics, digital, OTC and CDMO losses are declining, though they still dilute core margins by close to 1.5 percentage points. Diagnostics could break even by the end of next fiscal.
- Emerging markets: The decline was mostly due to Brazil, where new dapagliflozin competition followed Lupin’s period of exclusivity; management expects to maintain the current baseline and grow through complex products over the next 3 to 5 years. Developed markets excluding emerging markets, the US and India grew solidly in the quarter.